DK3105324T3 - Ngs-systemkontrol og fremgangsmåder omfattende disse - Google Patents
Ngs-systemkontrol og fremgangsmåder omfattende disse Download PDFInfo
- Publication number
- DK3105324T3 DK3105324T3 DK15709555.5T DK15709555T DK3105324T3 DK 3105324 T3 DK3105324 T3 DK 3105324T3 DK 15709555 T DK15709555 T DK 15709555T DK 3105324 T3 DK3105324 T3 DK 3105324T3
- Authority
- DK
- Denmark
- Prior art keywords
- nucleic acid
- control
- sample
- sequence
- next generation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6869—Methods for sequencing
- C12Q1/6874—Methods for sequencing involving nucleic acid arrays, e.g. sequencing by hybridisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/166—Oligonucleotides used as internal standards, controls or normalisation probes
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (12)
1. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering omfattende at ekstrahere nukleinsyremateriale fra en prøve og mindst en kontrolprøve, hvor kontrolprøven forberedes inden ekstraktion, endvidere omfattende at underkaste det ekstraherede nukleinsyremateriale for en Next Generation Sekventerings-fremgangsmåde, hvor kontrolprøven omfatter prøvemateriale suppleret med en nukleinsyrekontrol, hvor nukleinsyrekontrollen omfatter mindst en nukleinsyrekontrolsekvens er der forskellig fra målnukleinsyresekvensen, og hvor kontrollen omfatter mindst en vildtype-nukleinsyresekvens og mindst en mutant af vildtype-nukleinsyresekvensen.
2. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering ifølge krav 1, hvor nukleinsyrekontrolsekvensen er valgt fra ikke-humane afledte nukleinsyrer, eller valgt fra virale nukleinsyrer.
3. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket som helst af kravene 1 og 2, hvor nukleinsyrekontrolsekvensen er valgt fra nukleinsyrer, der er afledt fra tobakmosaikvirus.
4. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket som helst af kravene 1 til 3, omfattende mindst to nukleinsyrekontroller som defineret i et hvilket som helst af kravene 1 til 3 i et forudbestemt forhold.
5. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket som helst af kravene 1 til 4, hvor fremgangsmåden er egnet til detekteringen af tilstedeværelse eller fraværet af sekvenser afledt fra et infektiøs agens eller af et onkogen.
6. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket som helst af kravene 1 til 5, hvor tilstedeværelsen eller fraværet af en målsekvens afledt fra et infektiøs agens eller af et onkogen og tilstedeværelsen af mindst en nukleinsyrekontrolsekvens efter sekventeringsreaktionen er tegn på fuldført nukleinsyreekstraktion fra prøverne.
7. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket som helst af kravene 1 til 6, endvidere omfattende en kontamineringskontrol.
8. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket helst af kravene 1 til 7, hvor kontamineringskontrollen omfatter mindst en nukleinsyrekontrol som defineret i kravene 1 til 3, hvor kontamineringskontrollen ikke omfatter prøvemateriale.
9. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket som helst af kravene 1 til 8, omfattende at underkaste kontamineringskontrollen for en målnukleinsyre-specifik sekventeringsreaktion.
10. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket som helst af kravene 1 til 9, omfattende at underkaste kontamineringskontrollen for en målnukleinsyre-specifik sekventeringsreaktion, hvor fraværet af detektering af en målnukleinsyre-specifik sekvens i kontamineringskontrollen og detekteringen af tilstedeværelsen afen kontrolnukleinsyre-specifik sekvens er tegn på fraværet af kontaminering.
11. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering eller målnukleinsyredetekterings-fremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket som helst af kravene 1 til 10, hvor kontrolnukleinsyren er til stede i en mængde på 0,1 til 10 fg efter ekstraktion af nukleinsyrerne fra prøverne.
12. Diagnosticeringsfremgangsmåde baseret på Next Generation Sekventering eller målnukleinsyredetekterings-fremgangsmåde baseret på Next Generation Sekventering ifølge et hvilket som helst af kravene 1 til 11, hvor prøven er en klinisk prøve afledt fra et menneske, og hvor kontrolnukleinsyren er et plasmid omfattende vildtype- og/eller mutantsekvenser af en ikke-human virus, valgt fra dyrevirusser, der ikke smitter mennesker, plantevirusser, eller hvor kontrolnukleinsyren er blevet kunstigt fremstillet og ikke har nogen naturlig ækvivalent.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201402249A GB201402249D0 (en) | 2014-02-10 | 2014-02-10 | NGS systems control and methods involving the same |
| PCT/IB2015/050990 WO2015118513A1 (en) | 2014-02-10 | 2015-02-10 | Ngs systems control and methods involving the same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3105324T3 true DK3105324T3 (da) | 2019-04-08 |
Family
ID=50390720
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15709555.5T DK3105324T3 (da) | 2014-02-10 | 2015-02-10 | Ngs-systemkontrol og fremgangsmåder omfattende disse |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US11104948B2 (da) |
| EP (1) | EP3105324B1 (da) |
| JP (1) | JP6630672B2 (da) |
| CN (1) | CN106257989B (da) |
| AU (1) | AU2015213570B2 (da) |
| DK (1) | DK3105324T3 (da) |
| ES (1) | ES2719412T3 (da) |
| GB (1) | GB201402249D0 (da) |
| PT (1) | PT3105324T (da) |
| TR (1) | TR201903795T4 (da) |
| WO (1) | WO2015118513A1 (da) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201411603D0 (en) * | 2014-06-30 | 2014-08-13 | Vela Operations Pte Ltd | Compositions for quantitative and/or semiquantitative mutation detection methods |
| ES2893000T3 (es) * | 2015-12-01 | 2022-02-07 | Seracare Life Sciences Inc | Materiales de referencia celulares multiplex |
| EP3354746B1 (en) * | 2017-01-30 | 2019-05-29 | Gregor Mendel Institute of Molecular Plant Biology GmbH | Novel spike-in oligonucleotides for normalization of sequence data |
| WO2020041449A1 (en) * | 2018-08-21 | 2020-02-27 | Zymo Research Corporation | Methods and compositions for tracking sample quality |
| CN110885883B (zh) * | 2018-11-21 | 2024-07-26 | 广州易锦生物技术有限公司 | Dna参照标准及其应用 |
| CN111944806A (zh) * | 2020-07-30 | 2020-11-17 | 上海韦翰斯生物医药科技有限公司 | 一种高通量测序污染检测用分子标签组及其应用 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8608850D0 (en) | 1986-04-11 | 1986-05-14 | Diatech Ltd | Packaging system |
| US5596132A (en) | 1990-03-12 | 1997-01-21 | Cornell Research Foundation, Inc. | Induction of resistance to virus diseases by transformation of plants with a portion of a plant virus genome involving a read-through replicase gene |
| WO1995021248A1 (en) | 1994-02-03 | 1995-08-10 | The Scripps Research Institute | Method for using tobacco mosaic virus to overproduce peptides and proteins |
| WO2000050632A2 (en) | 1999-02-22 | 2000-08-31 | Lynx Therapeutics, Inc. | Polymorphic dna fragments and uses thereof |
| PT1282697E (pt) | 2000-03-28 | 2008-02-01 | Univ Queensland | Construção capaz de libertação na forma circular fechada a partir de uma grande sequência nucleotídica permitindo a expressão específica do local e/ou a expressão regulada durante o desenvolvimento de sequências genéticas seleccionadas |
| EP1579002B1 (en) * | 2002-12-13 | 2014-02-12 | Geneohm Sciences Canada, Inc. | Methods to verify the efficiency of sample preparation and nucleic acid amplification and/or detection |
| WO2011103467A2 (en) | 2010-02-19 | 2011-08-25 | Life Technologies Corporation | Methods and systems for nucleic acid sequencing validation, calibration and normalization |
| WO2012125848A2 (en) | 2011-03-16 | 2012-09-20 | Baylor College Of Medicine | A method for comprehensive sequence analysis using deep sequencing technology |
| CA2867293C (en) * | 2012-03-13 | 2020-09-01 | Abhijit Ajit PATEL | Measurement of nucleic acid variants using highly-multiplexed error-suppressed deep sequencing |
| WO2013166444A2 (en) * | 2012-05-04 | 2013-11-07 | Boreal Genomics Corp. | Biomarker analysis using scodaphoresis |
| GB201208942D0 (en) * | 2012-05-21 | 2012-07-04 | Vela Operations Pte Ltd | Extraction control for RNA |
| CA3043574C (en) * | 2012-11-26 | 2023-09-19 | The University Of Toledo | Methods for standardized sequencing of nucleic acids and uses thereof |
-
2014
- 2014-02-10 GB GB201402249A patent/GB201402249D0/en not_active Ceased
-
2015
- 2015-02-10 EP EP15709555.5A patent/EP3105324B1/en active Active
- 2015-02-10 US US15/117,656 patent/US11104948B2/en active Active
- 2015-02-10 DK DK15709555.5T patent/DK3105324T3/da active
- 2015-02-10 JP JP2016544852A patent/JP6630672B2/ja active Active
- 2015-02-10 PT PT15709555T patent/PT3105324T/pt unknown
- 2015-02-10 ES ES15709555T patent/ES2719412T3/es active Active
- 2015-02-10 CN CN201580008082.7A patent/CN106257989B/zh active Active
- 2015-02-10 WO PCT/IB2015/050990 patent/WO2015118513A1/en active Application Filing
- 2015-02-10 TR TR2019/03795T patent/TR201903795T4/tr unknown
- 2015-02-10 AU AU2015213570A patent/AU2015213570B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20180037949A1 (en) | 2018-02-08 |
| US11104948B2 (en) | 2021-08-31 |
| WO2015118513A1 (en) | 2015-08-13 |
| ES2719412T3 (es) | 2019-07-10 |
| AU2015213570A1 (en) | 2016-06-16 |
| CN106257989A (zh) | 2016-12-28 |
| JP6630672B2 (ja) | 2020-01-15 |
| EP3105324A1 (en) | 2016-12-21 |
| GB201402249D0 (en) | 2014-03-26 |
| CN106257989B (zh) | 2020-04-28 |
| PT3105324T (pt) | 2019-04-01 |
| JP2017505120A (ja) | 2017-02-16 |
| TR201903795T4 (tr) | 2019-06-21 |
| EP3105324B1 (en) | 2018-12-19 |
| AU2015213570B2 (en) | 2020-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3105324T3 (da) | Ngs-systemkontrol og fremgangsmåder omfattende disse | |
| EP1877576B1 (en) | Methods for determining sequence variants using ultra-deep sequencing | |
| EP2341151B1 (en) | Methods for determining sequence variants using ultra-deep sequencing | |
| US20180195118A1 (en) | Systems and methods for detection of genomic copy number changes | |
| JP7391877B2 (ja) | 癌におけるマイクロサテライト不安定性を検出するためのバイオマーカーパネル及び方法 | |
| CN110964814B (zh) | 用于核酸序列变异检测的引物、组合物及方法 | |
| JP2010521156A (ja) | Ｈｉｖ薬物耐性バリアントの検出のためのシステムおよび方法 | |
| US20210246499A1 (en) | Detection of short homopolymeric repeats | |
| US20160208240A1 (en) | Ngs workflow | |
| JP2019528705A5 (da) | ||
| US20170137807A1 (en) | Improved ngs workflow | |
| RU2642273C1 (ru) | Способ дифференциации штаммов Yersinia pestis на основной и неосновные подвиды методом ПЦР в режиме реального времени | |
| JP6468555B2 (ja) | 検出キット，及び検出方法 | |
| JP2018102252A (ja) | 検出キット，及び検出方法 | |
| JP2008061545A (ja) | 黄色ブドウ球菌のコアグラーゼ型別用オリゴヌクレオチド |